✦ LIBER ✦

Bioavailability in man of atenolol and chlorthalidone from a combination formulation

✍ Scribed by James McAinsh; Brian H. Holmes; Timothy J. Fitzsimons; Jean Young

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 438 KB
Volume: 7
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.2510070303

No coin nor oath required. For personal study only.

✦ Synopsis

In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drugs as a fixed combination ('Tenoret 50'). as a free combination, and individually, at doses of 50mg atenolol and 12.5mg chlorthalidone.

There were no statistically or clinically significant differences between the three treatments of atenolol in terms of individual blood levels, areas under the curve, and urinary excretion. The mean half-lives were between 5 and 7 h, in agreement with other published data. The variation in peak systemic levels is less than that observed for a number of other @-blocking drugs and is of the same order as seen in other investigations involving atenolol. Thus the bioavailability of atenolol from the fixed combination is equivalent to that from the free combination and from the atenolol tablet.

The mean peak blood concentrations of chlorthalidone were 0.94, 140. and 0.99 pg mi-' for the fixed and free combinations and the chlorthalidone tablet, respectively. The mean areas under the curve were also similar as were the mean half-lives and urinary recovery. There were no statistically or clinically significant differences between the three treatments. Thus the bioavailability of chlorthalidone from the fixed combination is equivalent to that from the free combination and from the chlorthalidone tablet.

It is concluded that combining chlorthalidone and atenolol in a single tablet does not affect the systemic bioavailability of either component.

📜 SIMILAR VOLUMES

Bioavailability in man of atenolol and c

Bioavailability in man of atenolol and chlorthalidone from a combination formulation

✍ James McAinsh; William Bastain; Jean Young; John D. Harry 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract In this comparative bioavailability study in 12 healthy volunteers the blood level profiles and urinary recoveries of both atenolol and chlorthalidone were studied following the administration of the drug as a fixed combination (‘Tenoretic’), as a free combination, and individually, at

Plasma concentrations and bioavailabilit

Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation

✍ L. F. Chasseaud; E. Doyle; T. Taylor; A. Darragh 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB 👁 1 views

## Abstract The plasma concentrations and bioavailability of sustained‐release isosorbide denigrate and standard‐release pindolol have been compared after administration of these drugs in combination and alone. Bioavailability parameters of isosorbide dinitrate and pindolol obtained after administ

Bioavailability of medroxalol in man

✍ Frederick J. Keeley; Daniel L. Weiner; Richard A. Okerholm 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB 👁 1 views

Ten healthy male volunteers received single oral doses of l00mg of medroxalol administered as a solution, a preliminary tablet formulation and a single dose of lOOmg administered intravenously in a randomized three-way crossover study. Mean terminal half-lives of 12.4, 13.4, and 11.3 h were observed

Bioavailability of terfenadine in man

✍ R. A. Okerholm; D. L. Weiner; R. H. Hook; B. J. Walker; G. A. Leeson; S. A. Bied 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

## Abstract Fourteen normal male subjects were given either 60 mg or 180mg of terfenadine suspension in a randomized two‐way crossover study. Peak plasma concentrations of 1.544 ± 0.726 (mean ± S.D.) ng ml^−1^ were obtained in 0.786 ± 0.426 h following the 60 mg dose and displayed an AUC of 11.864

Comparative in vitro and in vivo bioavai

Comparative in vitro and in vivo bioavailability of naproxen from tablet and caplet formulations

✍ B. G. Charles; G. A. G. Mogg 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

## Abstract A 500 mg dose of naproxen in a caplet formulation (product A) or a tablet (Naprosyn 500, product B) was administered to 14 fasting healthy subjects on two separate occasions, separated by a 1–2 week washout period in an open, randomized crossover. Blood samples were drawn periodically a

Systemic bioavailability of acebutolol i

Systemic bioavailability of acebutolol in man

✍ A. Roux; B. Flouvat; Y. Fouache; J. P. Bourdarias 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 1 views